{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:09:19Z","timestamp":1780618159540,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,10]],"date-time":"2027-02-10T00:00:00Z","timestamp":1802217600000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clon.2026.104058","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:25:23Z","timestamp":1769099123000},"page":"104058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Risk of Symptomatic Skeletal Events After Discontinuation of Long-term Denosumab in Patients With Bone Metastases: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8369-1019","authenticated-orcid":false,"given":"H.","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fukase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-3777","authenticated-orcid":false,"given":"R.","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Takemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-4095","authenticated-orcid":false,"given":"T.","family":"Akisue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clon.2026.104058_bib1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.clon.2026.104058_bib2","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.clon.2026.104058_bib3","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9768","key":"10.1016\/j.clon.2026.104058_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clon.2026.104058_bib5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clon.2026.104058_bib6","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clon.2026.104058_bib7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clon.2026.104058_bib8","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mds175","article-title":"Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104058_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100423","article-title":"Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach","volume":"34","author":"Jacobson","year":"2022","journal-title":"J Bone Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104058_bib10","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.clon.2026.104058_bib11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.clon.2026.104058_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.clon.2026.104058_bib13","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104058_bib14","first-page":"925","article-title":"Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review","volume":"29","author":"Ng","year":"2021","journal-title":"Support Care Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:29:20Z","timestamp":1773455360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":14,"alternative-id":["S0936655526000294"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104058","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Symptomatic Skeletal Events After Discontinuation of Long-term Denosumab in Patients With Bone Metastases: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104058"}}